Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 72,100 shares, a growth of 281.5% from the January 31st total of 18,900 shares. Approximately 2.6% of the shares of the company are sold short. Based on an average daily volume of 42,900 shares, the short-interest ratio is presently 1.7 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Kiora Pharmaceuticals in a research note on Tuesday, November 12th.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A hedge fund recently raised its stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC increased its position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,221 shares of the company’s stock after buying an additional 3,670 shares during the quarter. ADAR1 Capital Management LLC owned about 6.67% of Kiora Pharmaceuticals worth $661,000 at the end of the most recent reporting period. 76.97% of the stock is owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Stock Down 0.9 %

Shares of NASDAQ:KPRX opened at $3.35 on Friday. The company has a 50 day moving average of $3.59 and a 200-day moving average of $3.55. Kiora Pharmaceuticals has a twelve month low of $3.00 and a twelve month high of $6.48.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.